Antigenics About
Antigenics: Lead
Products in Development at Antigenics Oncophage®
(HSPPC-96) and AG-858 (HSPPC-70) are investigational personalized cancer vaccines
based on Antigenics’ heat shock protein technology. Oncophage
has received fast track and orphan drug designations from the US Food and Drug
Administration for both kidney cancer and metastatic melanoma. AG-858
vaccine is in clinical trails in combination treatment for chronic
myelogenous leukemia. Both
Oncophage® (HSPPC-96) and
AG-858 (HSPPC-70) vaccines are designed to reprogram the immune system
to target cancer cells while leaving healthy cells unaffected. Aroplatin
is currently being evaluated as a monotherapy in for colon
cancer and advanced solid tumors.
AG-702
is an investigational vaccine for genital
herpes treatment based on proprietary heat shock protein technology.
Key
Statistics fo
Antigenics
Antigenics Inc. is a biotechnology firm developing products to treat cancers,
infectious diseases and autoimmune disorders.
More on Antigenics:
Basic Chart
for Antigenics
Analyst
Opinion
Analysts
Estimates